首頁 > 市場調查報告書 > 製藥

癌症

胃癌藥物市場規模、佔有率、成長分析（按類型、按治療類型、按藥物類型、按給藥途徑、按最終用戶、按地區）- 行業預測，2025 年至 2032 年

市場調查報告書

商品編碼

1764770

胃癌藥物市場規模、佔有率、成長分析（按類型、按治療類型、按藥物類型、按給藥途徑、按最終用戶、按地區）- 行業預測，2025 年至 2032 年

Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Type (Adenocarcinoma, Lymphoma), By Treatment Type (Chemotherapy, Targeted Therapy), By Drug Type, By Route of Administration, By End-Users, By Region - Industry Forecast 2025-2032

出版日期: 2025年07月02日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球胃癌藥物市場規模為 54 億美元，預計將從 2024 年的 60.2 億美元成長到 2032 年的 143.8 億美元，預測期內（2025-2032 年）的複合年成長率為 11.5%。

在發病率上升和藥物研發取得重大進展的推動下，全球胃癌治療市場可望經歷動態成長。肥胖、吸煙和幽門螺旋桿菌感染等風險因素的日益普及推動了對有效治療方法的需求。標靶治療和免疫療法等創新治療方法正在徹底改變治療方法並改善患者預後。在醫療成本上升、研發投入強勁和法規環境支持性的推動下，製藥公司、生物製藥公司和學術機構之間的策略聯盟正在促進下一代療法的推出。然而，市場發展面臨開發成本高、監管嚴格以及低收入地區藥物取得有限等挑戰。儘管如此，多樣化的藥物管線加上多標靶和個人化治療的潛力表明未來前景光明。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益同比對比（2022-2024 年）

主要企業簡介

Imugene Limited（Australia）
Otsuka Pharmaceuticals Co., Ltd（Japan）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Bristol-Myers Squibb Company（US）
Novartis AG（Switzerland）
Lilly（US）
Sanofi（France）
Amgen Inc.（US）
Bayer AG（Germany）
Gilead Sciences, Inc.（US）
AstraZeneca（UK）
Ipsen Pharma（France）
Takeda Pharmaceutical Company Limited（Japan）
Biosplice Therapeutics, Inc.（US）
Arbutus Biopharma（Canada）
ASLAN Pharmaceuticals（Singapore）

結論和建議

簡介目錄

Product Code: SQMIG35I2393

Global Gastric Cancer Drugs Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 6.02 billion in 2024 to USD 14.38 billion by 2032, growing at a CAGR of 11.5% during the forecast period (2025-2032).

The global gastric cancer drugs market is poised for dynamic growth, driven by rising incidence rates and significant advancements in drug development. Increased prevalence of risk factors like obesity, smoking, and Helicobacter pylori infections is escalating the demand for effective therapies. Innovations such as targeted therapies and immunotherapies are revolutionizing treatment modalities and improving patient outcomes. Boosted by higher healthcare spending, robust R&D investments, and supportive regulatory environments, strategic partnerships among drug companies, biopharmaceutical firms, and academic institutions are facilitating the introduction of next-generation treatments. However, market growth faces challenges, including high development costs, stringent regulations, and limited access in low-income regions. Nonetheless, a diverse drug pipeline, coupled with potential multi-targeted and personalized therapies, indicates a promising future ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Cancer Drugs Market Segments Analysis

Global Gastric Cancer Drugs Market is segmented by Type, Treatment Type, Drug Type, Route of Administration, End-Users and region. Based on Type, the market is segmented into Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation Therapy, Medication and Others. Based on Drug Type, the market is segmented into Doxorubicin Hydrochloride, Sunitinib, Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market is experiencing significant growth driven by the rapid development and approval of targeted therapies and immunotherapies. Advanced treatment options, including HER2 inhibitors and PD-1/PD-L1 checkpoint inhibitors, offer enhanced efficacy and improved safety compared to traditional chemotherapy. By effectively targeting specific genetic mutations and immune checkpoints, these innovations have unlocked new therapeutic possibilities, leading to better outcomes and increased survival rates for many gastric cancer patients. As pivotal clinical trials validate the effectiveness of these novel treatments, regulatory bodies and healthcare professionals are swiftly integrating them into practice, further propelling market expansion.

Restraints in the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market faces substantial challenges primarily due to the prohibitive costs associated with new targeted therapies and immunotherapies. These innovative treatments often come with premium price tags, a consequence of significant research and development expenses, intricate manufacturing processes, and the need for companion diagnostics. As a result, access to these advanced therapies is largely determined by financial capability, making it difficult for patients in low- and middle-income countries to obtain them. Even in high-income nations, reimbursement obstacles and budget constraints further hinder widespread adoption, restricting patient access and slowing overall market growth.

Market Trends of the Global Gastric Cancer Drugs Market

The global gastric cancer drugs market is experiencing a significant transformation, driven by rapid advancements in artificial intelligence (AI) and data analytics. AI technologies are enhancing drug development processes, allowing for more personalized treatment options tailored to the genetic profiles of patients. This trend not only optimizes therapeutic effectiveness but also improves patient outcomes, ultimately driving increased adoption of innovative drug formulations. Additionally, the integration of AI in clinical decision-making is enabling healthcare professionals to make more informed choices, resulting in a more strategic approach to managing gastric cancer. As a result, the market is poised for substantial growth, with ongoing investments in research and development further propelling innovation.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies

Global Gastric Cancer Drugs Market Size by Type & CAGR (2025-2032)

Market Overview
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others

Global Gastric Cancer Drugs Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Surgery
Radiation Therapy
Medication
Others

Global Gastric Cancer Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Doxorubicin Hydrochloride
Sunitinib
Mitomycin
Imatinib
Fluorouracil
Trastuzumab
Others

Global Gastric Cancer Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable

Global Gastric Cancer Drugs Market Size by End-Users & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Gastric Cancer Drugs Market Size & CAGR (2025-2032)

North America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- US
- Canada
Europe (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Imugene Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosplice Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ASLAN Pharmaceuticals (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments